To view speaker biographies and session abstracts,
click Expand All or the + next to each title.
Registration will begin at 9:00 a.m. Pre-registration is required to attend.
Downstream process development for monoclonal antibodies (mAbs) has become an exercise in efficiency due to the desire to be fast-to-clinic. Many companies have resorted to using a purification platform to decrease timelines. With the onset of high-throughput process development, development timelines and material requirements could be further decreased. Here, we demonstrate the synergy of utilizing high-throughput development with an existing downstream platform to enable mAb drug candidates to be brought to clinical trials faster. Using pre-determined and antibody-compatible parameters, a lean phase 1 downstream process was developed. Final conditions were determined based on maximum process yield and aggregate clearance. This study also served to show the comparability between microliter-scale (Tecan with RoboColumns®) and milliliter-scale (AKTA® with small-scale columns) development.
There is no charge for attendance but registration is required. Seats are limited to end-users of bioprocessing tools and technologies.
Travel, accommodations, and incidental expenses are the responsibility of attendees. Lunch will be served.